Monopar CEO sells 29,056 shares under plan

Posted by Lindsey Winhoffer on Sep 29th, 2026

What happened

Monopar Therapeutics (NASDAQ: MNPR) Chief Executive Officer and director Chandler Robinson reported option exercises and sales on 2026-09-24. The Form 4 says he exercised 14,056 shares at a $30 exercise price and 15,000 shares at a $14 exercise price, lifting the direct holding before sales to 128,323 shares.

It also says he sold 29,056 shares in four tranches for about $2.56 million. The sale blocks were 10,450 shares at $87.15, 9,638 at $87.96, 8,368 at $88.97 and 600 at $89.79. The filing was signed on 2026-09-28. After the transactions, Robinson held 99,267 shares directly. The form also lists 62,815 shares held indirectly by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.

Key numbers

Metric	Latest	Source
Shares sold	29,056 shares	SEC Form 4
Sale price range	from $87.15 to $89.79 per share	SEC Form 4
Sale proceeds	about $2.56 million	SEC Form 4
Shares held after sale	99,267 shares	SEC Form 4
Shares sold as share of prior holding	22.6%	Calculated from SEC Form 4

Why it matters

For a pre-revenue biotech, this is an ownership update, not a pipeline update. The reported sales equal 22.6% of the 128,323-share holding before the sales after the option exercises, so the trim was sizable relative to that base. That makes the sale easier to read as prearranged than discretionary. The counterpoint is that the filing says the transactions were made under a Rule 10b5-1 trading plan executed on June 25, 2026.

Robinson still held 99,267 shares directly after the reported sales, and the trust account adds another 62,815 shares indirectly. That continued exposure is why this reads as a partial trim, not a full exit. For investors, the filing mainly sets a baseline for insider ownership rather than a new operating signal. It is not a verdict on the company.

What's next

Monopar Therapeutics' next quarterly report is the next scheduled check on this baseline. A future update with clinical or partnering progress would matter more to the stock case than another routine Form 4. Additional sales under the same plan would add to the ownership read, while a stable holding pattern would keep this filing's signal unchanged. That is the baseline this filing creates.

Sources

SEC Form 4 — Statement of changes in beneficial ownership filed 2026-09-28.

Read the full OptimistFi thesis on Monopar Therapeutics: https://optimistfi.com/stocks/MNPR

See what would break the Monopar Therapeutics thesis and track it live on the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

The full Monopar Therapeutics investment case, its status and the next test to watch live on the Monopar Therapeutics thesis page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.